Clinical Trials
15 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02537548 2026-05-27
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
University of Southern California
Phase NA Active not recruiting
NCT07601672 2026-05-22
PRISTINE
Istituto Clinico Humanitas
Phase NA Not yet recruiting
NCT07218913 2026-04-17
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
Phase 1 Recruiting
NCT07498959 2026-03-27
TESTIGO
Sahlgrenska University Hospital
Phase NA Recruiting
NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting
NCT03158064 2026-01-28
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03937843 2026-01-20
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT04876456 2026-01-15
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Indiana University
Phase 2 Active not recruiting
NCT05345158 2025-12-19
R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
University Health Network, Toronto
Phase NA Recruiting
NCT02341989 2025-12-02
SWENOTECA-ABC
St. Olavs Hospital
Phase 3 Active not recruiting
NCT06133543 2025-09-15
RAISN
Heinrich-Heine University, Duesseldorf
Phase NA Recruiting
NCT06144736 2025-09-15
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
Heinrich-Heine University, Duesseldorf
Phase 2 Recruiting
NCT06418789 2025-08-03
GERMAN
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Recruiting
NCT06932458 2025-07-20
RPLND-Seminoma
Western University, Canada
Phase 2 Recruiting